SCHEMBL4723344

SCHEMBL4723344

CCCOC1(c2cccc3ccccc23)COCC[N]1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.35
SLC6A2 P23975 4/20 0.35
SLC6A4 P31645 4/20 0.35
HTR1B P28222 3/20 0.33
MEN1 O00255 2/20 0.31
MAPT P10636 2/20 0.31
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
CNR1 P21554 1/20 0.30
CNR2 P34972 1/20 0.30
HTR1D P28221 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
HTR1A P08908 1/20 0.30
HTR7 P34969 1/20 0.30
HTR2B P41595 1/20 0.30
TMEM97 Q5BJF2 1/20 0.30
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720437 0.93 L3MBTL1 (0.36) SLC6A3SLC6A2SLC6A4HTR1BCNR1
SCHEMBL4720742 0.90 SLC6A3 (0.36) SLC6A3SLC6A2SLC6A4MEN1MAPT
SCHEMBL4720972 0.83 SLC6A3 (0.36) SLC6A3SLC6A2SLC6A4MEN1MAPT
SCHEMBL4722969 0.82 SLC6A3 (0.44) SLC6A3SLC6A2SLC6A4HTR1BMEN1
SCHEMBL4723127 0.81 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4HTR1BMEN1
SCHEMBL4724737 0.80 HTR1A (0.38) MEN1KMT2ANPSR1HTR1A
SCHEMBL4720403 0.78 SLC6A3 (0.35) SLC6A3SLC6A2SLC6A4HTR1BMEN1
SCHEMBL4724348 0.78 SLC6A2 (0.35) SLC6A3SLC6A2SLC6A4HTR1BMEN1
SCHEMBL4721684 0.75 SLC6A3 (0.42) SLC6A3SLC6A2SLC6A4HTR1BCNR1
SCHEMBL4722937 0.74 SLC6A3 (0.44) SLC6A3SLC6A2SLC6A4HTR1BCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 SLC6A3 2115/4885SLC6A2 3030/4885SLC6A4 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.